(CI) Cigna - Ratings and Ratios
Insurance, Pharmacy, Medicare, Dental, International
Dividends
| Dividend Yield | 2.20% |
| Yield on Cost 5y | 3.25% |
| Yield CAGR 5y | 243.98% |
| Payout Consistency | 85.1% |
| Payout Ratio | 21.3% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 41.4% |
| Value at Risk 5%th | 48.4% |
| Relative Tail Risk | -28.84% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.08 |
| Alpha | -15.41 |
| CAGR/Max DD | -0.12 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.253 |
| Beta | 0.121 |
| Beta Downside | -0.044 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.10% |
| Mean DD | 12.56% |
| Median DD | 12.61% |
Description: CI Cigna December 02, 2025
The Cigna Group (CI) operates two primary segments: Evernorth Health Services, which delivers pharmacy-benefit management, specialty pharmacy, home-delivery, and broader care-coordination solutions to insurers, employers and government entities; and Cigna Healthcare, which sells medical, pharmacy, behavioral-health, dental and Medicare (Advantage, Supplement, Part D) products to both insured and self-insured customers, plus international and expatriate coverage.
In FY 2023 the company reported total revenue of roughly **$180 billion**, with an adjusted operating margin of **5.5 %**, reflecting steady growth in its PBM business (approximately **6 % YoY** enrollment increase) and modest expansion in Medicare Advantage enrollment (+3 % YoY). Net income rose to **$2.6 billion**, driven by cost-containment initiatives in specialty pharmacy and higher-margin commercial lines.
Key drivers for Cigna’s outlook include: (1) the **aging U.S. population**, which sustains demand for Medicare products; (2) **inflationary pressure on medical and drug costs**, prompting insurers to seek value-based contracts and cost-sharing mechanisms; and (3) **regulatory trends** such as the 2024 CMS rule tightening pharmacy-benefit transparency, which could create both compliance costs and opportunities for PBM differentiation.
For a deeper quantitative view, see the ValueRay analysis of CI.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (6.15b TTM) > 0 and > 6% of Revenue (6% = 16.09b TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 1.42pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -3.62% (prev -3.37%; Δ -0.25pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 8.66b > Net Income 6.15b (YES >=105%, WARN >=100%) |
| Net Debt (28.02b) to EBITDA (12.38b) ratio: 2.26 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (268.2m) change vs 12m ago -4.71% (target <= -2.0% for YES) |
| Gross Margin 10.03% (prev 11.21%; Δ -1.18pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 169.9% (prev 147.5%; Δ 22.40pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.88 (EBITDA TTM 12.38b / Interest Expense TTM 1.41b) >= 6 (WARN >= 3) |
Altman Z'' 1.38
| (A) -0.06 = (Total Current Assets 46.73b - Total Current Liabilities 56.45b) / Total Assets 157.92b |
| (B) 0.30 = Retained Earnings (Balance) 47.03b / Total Assets 157.92b |
| (C) 0.06 = EBIT TTM 9.68b / Avg Total Assets 157.78b |
| (D) 0.38 = Book Value of Equity 44.23b / Total Liabilities 115.91b |
| Total Rating: 1.38 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.59
| 1. Piotroski 6.50pt |
| 2. FCF Yield 7.57% |
| 3. FCF Margin 2.77% |
| 4. Debt/Equity 0.81 |
| 5. Debt/Ebitda 2.26 |
| 6. ROIC - WACC (= 6.82)% |
| 7. RoE 15.06% |
| 8. Rev. Trend 96.03% |
| 9. EPS Trend 79.08% |
What is the price of CI shares?
Over the past week, the price has changed by +4.23%, over one month by +2.44%, over three months by -7.03% and over the past year by +2.59%.
Is CI a buy, sell or hold?
- Strong Buy: 13
- Buy: 6
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 328.7 | 19.7% |
| Analysts Target Price | 328.7 | 19.7% |
| ValueRay Target Price | 272.9 | -0.7% |
CI Fundamental Data Overview December 11, 2025
P/E Trailing = 11.6295
P/E Forward = 8.6505
P/S = 0.2618
P/B = 1.684
P/EG = 0.5308
Beta = 0.263
Revenue TTM = 268.13b USD
EBIT TTM = 9.68b USD
EBITDA TTM = 12.38b USD
Long Term Debt = 30.95b USD (from longTermDebt, last quarter)
Short Term Debt = 3.09b USD (from shortTermDebt, last quarter)
Debt = 34.04b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 28.02b USD (from netDebt column, last quarter)
Enterprise Value = 98.19b USD (70.18b + Debt 34.04b - CCE 6.03b)
Interest Coverage Ratio = 6.88 (Ebit TTM 9.68b / Interest Expense TTM 1.41b)
FCF Yield = 7.57% (FCF TTM 7.44b / Enterprise Value 98.19b)
FCF Margin = 2.77% (FCF TTM 7.44b / Revenue TTM 268.13b)
Net Margin = 2.29% (Net Income TTM 6.15b / Revenue TTM 268.13b)
Gross Margin = 10.03% ((Revenue TTM 268.13b - Cost of Revenue TTM 241.24b) / Revenue TTM)
Gross Margin QoQ = 8.52% (prev 11.73%)
Tobins Q-Ratio = 0.62 (Enterprise Value 98.19b / Total Assets 157.92b)
Interest Expense / Debt = 1.02% (Interest Expense 347.0m / Debt 34.04b)
Taxrate = 14.03% (322.0m / 2.29b)
NOPAT = 8.32b (EBIT 9.68b * (1 - 14.03%))
Current Ratio = 0.83 (Total Current Assets 46.73b / Total Current Liabilities 56.45b)
Debt / Equity = 0.81 (Debt 34.04b / totalStockholderEquity, last quarter 41.80b)
Debt / EBITDA = 2.26 (Net Debt 28.02b / EBITDA 12.38b)
Debt / FCF = 3.77 (Net Debt 28.02b / FCF TTM 7.44b)
Total Stockholder Equity = 40.82b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.89% (Net Income 6.15b / Total Assets 157.92b)
RoE = 15.06% (Net Income TTM 6.15b / Total Stockholder Equity 40.82b)
RoCE = 13.49% (EBIT 9.68b / Capital Employed (Equity 40.82b + L.T.Debt 30.95b))
RoIC = 11.46% (NOPAT 8.32b / Invested Capital 72.63b)
WACC = 4.64% (E(70.18b)/V(104.22b) * Re(6.46%) + D(34.04b)/V(104.22b) * Rd(1.02%) * (1-Tc(0.14)))
Discount Rate = 6.46% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -4.59%
[DCF Debug] Terminal Value 79.10% ; FCFE base≈6.54b ; Y1≈6.92b ; Y5≈8.23b
Fair Price DCF = 539.5 (DCF Value 144.12b / Shares Outstanding 267.1m; 5y FCF grow 6.47% → 3.0% )
EPS Correlation: 79.08 | EPS CAGR: 14.13% | SUE: 0.27 | # QB: 0
Revenue Correlation: 96.03 | Revenue CAGR: 11.89% | SUE: 1.78 | # QB: 11
EPS next Quarter (2026-03-31): EPS=7.30 | Chg30d=-0.024 | Revisions Net=-13 | Analysts=20
EPS next Year (2026-12-31): EPS=30.75 | Chg30d=-0.143 | Revisions Net=-21 | Growth EPS=+3.8% | Growth Revenue=+4.8%
Additional Sources for CI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle